Valeo Pharma Inc.
VPHIF · OTC
10/31/2023 | 10/31/2022 | 10/31/2021 | 10/31/2020 | |
|---|---|---|---|---|
| Market Cap | $13 | $54 | $59 | $53 |
| - Cash | $8 | $23 | $2 | $3 |
| + Debt | $65 | $61 | $8 | $3 |
| Enterprise Value | $70 | $93 | $64 | $53 |
| Revenue | $54 | $28 | $14 | $7 |
| % Growth | 94.3% | 104.7% | 81.5% | – |
| Gross Profit | $13 | $6 | $4 | $1 |
| % Margin | 24.3% | 22.6% | 29.2% | 18.5% |
| EBITDA | -$11 | -$16 | -$11 | -$4 |
| % Margin | -21.1% | -58% | -81% | -50.1% |
| Net Income | -$28 | -$26 | -$14 | -$5 |
| % Margin | -51.6% | -92.8% | -105% | -63.7% |
| EPS Diluted | -0.32 | -0.32 | -0.2 | -0.082 |
| % Growth | 0% | -60% | -143.3% | – |
| Operating Cash Flow | -$16 | -$29 | -$12 | -$5 |
| Capital Expenditures | -$6 | -$7 | -$3 | -$1 |
| Free Cash Flow | -$21 | -$35 | -$16 | -$7 |